Hexiris Ophthalmics

Home
Hexiris Ophthalmics

Hexiris is developing a new generation of ophthalmic devices designed to simplify glaucoma treatment and expand access to care.

We make Interventional Glaucoma (IG) treatment accessible to more patients worldwide.

11/09/2026

A landmark September for Hexiris. This fall, we’re bringing the OBi™ platform and our first in human clinical results to five major ophthalmology meetings across Europe and North America.

It starts today at the Ophthalmology Futures Forum in London, where co founder Dr. Nir Shoham Hazon presented Hexiris and our early clinical experience with OBi™ Core. From London to Ottawa, Halifax, and New Orleans, we’re putting our technology into the hands of ophthalmologists and continuing the conversation around a simple question:

Read the full press release here: https://www.globenewswire.com/news-release/2026/09/10/3359185/0/en/hexiris-ophthalmics-to-present-first-in-human-obi-glaucoma-data-at-five-fall-meetings-beginning-with-the-ophthalmology-futures-forum-in-london.html

𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘴𝘵𝘢𝘵𝘶𝘴 𝘷𝘢𝘳𝘪𝘦𝘴 𝘣𝘺 𝘱𝘳𝘰𝘥𝘶𝘤𝘵 𝘢𝘯𝘥 𝘫𝘶𝘳𝘪𝘴𝘥𝘪𝘤𝘵𝘪𝘰𝘯. 𝘖𝘉𝘪™ 𝘊𝘰𝘳𝘦 𝘩𝘰𝘭𝘥𝘴 𝘢 𝘏𝘦𝘢𝘭𝘵𝘩 𝘊𝘢𝘯𝘢𝘥𝘢 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦 𝘭𝘪𝘤𝘦𝘯𝘴𝘦 𝘢𝘯𝘥 𝘪𝘴 𝘍𝘋𝘈 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥. 𝘖𝘉𝘪™ 𝘎𝘰𝘯, 𝘖𝘉𝘪™ 𝘚𝘩𝘶𝘯𝘵, 𝘢𝘯𝘥 𝘖𝘉𝘪™ 𝘚𝘱𝘢𝘤𝘦𝘳 𝘢𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴, 𝘊𝘢𝘯𝘢𝘥𝘢, 𝘰𝘳 𝘵𝘩𝘦 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘜𝘯𝘪𝘰𝘯, 𝘦𝘹𝘤𝘦𝘱𝘵 𝘸𝘩𝘦𝘳𝘦 𝘴𝘱𝘦𝘤𝘪𝘧𝘪𝘤𝘢𝘭𝘭𝘺 𝘢𝘶𝘵𝘩𝘰𝘳𝘪𝘻𝘦𝘥.

07/09/2026

September is a big month for Hexiris as we head to three meetings across Europe and Canada.

From ESCRS in London to the CGS Annual Meeting in Halifax and the Sally Letson Symposium in Ottawa, there will be plenty of opportunities to meet the Hexiris team and experience the OBi™ platform.
Save the dates and come say hello.

𝘈𝘭𝘭 𝘏𝘦𝘹𝘪𝘳𝘪𝘴 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴 𝘢𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.

04/09/2026

What happens when access becomes the focus? In our latest issue of Expanding Access we take you from the COS floor in Montreal to a vision mission in Mexico, and into the research shaping the future of interventional glaucoma care.

Subscribe to Expanding Access and follow the journey to learn more.

31/08/2026

OBi™ Shunt is being designed to support sustained intraocular pressure reduction following minimally invasive bleb procedures. It combines a silicone implant with an intuitive delivery system that can be used in both office-based and surgical settings. As part of the Hexiris platform, it reflects our vision of making interventional glaucoma care more accessible through practical, minimally invasive technologies.

𝘖𝘉𝘪™ 𝘚𝘩𝘶𝘯𝘵 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦 𝘢𝘯𝘥 𝘪𝘴 𝘯𝘰𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴, 𝘊𝘢𝘯𝘢𝘥𝘢, 𝘰𝘳 𝘵𝘩𝘦 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘜𝘯𝘪𝘰𝘯.

26/08/2026

Minimally invasive bleb surgery creates a new drainage pathway for aqueous humor, lowering intraocular pressure by filtering fluid beneath the conjunctiva.

Traditionally, bleb-forming surgery meant trabeculectomy: effective, but invasive and OR-bound.

MIBS intends to simplify the concept and with OBi™ Core, it can be performed at the slit lamp in an office setting.

Education is the first step to access.

𝘖𝘉𝘪™ 𝘊𝘰𝘳𝘦 𝘪𝘴 𝘏𝘦𝘢𝘭𝘵𝘩 𝘊𝘢𝘯𝘢𝘥𝘢 𝘢𝘶𝘵𝘩𝘰𝘳𝘪𝘻𝘦𝘥 𝘢𝘯𝘥 𝘍𝘋𝘈 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥. 𝘖𝘵𝘩𝘦𝘳 𝘏𝘦𝘹𝘪𝘳𝘪𝘴 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴 𝘢𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴, 𝘊𝘢𝘯𝘢𝘥𝘢, 𝘰𝘳 𝘵𝘩𝘦 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘜𝘯𝘪𝘰𝘯

24/08/2026

Comprehensive ophthalmologists are increasingly looking for ways to expand the care they can provide within their own practice. OBi™ Shunt design is intended to support office-based interventional glaucoma care through a streamlined procedure performed at the slit lamp, without the need for complex operating room infrastructure.
The goal is simple: help make earlier intervention more accessible for both physicians and patients.

𝘖𝘉𝘪™ 𝘊𝘰𝘳𝘦 𝘪𝘴 𝘏𝘦𝘢𝘭𝘵𝘩 𝘊𝘢𝘯𝘢𝘥𝘢 𝘢𝘶𝘵𝘩𝘰𝘳𝘪𝘻𝘦𝘥 𝘢𝘯𝘥 𝘍𝘋𝘈 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥. 𝘖𝘵𝘩𝘦𝘳 𝘏𝘦𝘹𝘪𝘳𝘪𝘴 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴 𝘢𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴, 𝘊𝘢𝘯𝘢𝘥𝘢, 𝘰𝘳 𝘵𝘩𝘦 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘜𝘯𝘪𝘰𝘯.

20/08/2026

Glaucoma care is constrained by three things: who can treat, where they can treat, and when they can treat.

Hexiris intends to address all three:
• WHO - enabling more ophthalmologists to perform interventional procedures
• WHERE - at the slit lamp, not only in the OR
• WHEN - earlier in the disease, without waiting lists

Together: the potential to expand access to interventional glaucoma care by ~3x.

𝘈𝘭𝘭 𝘏𝘦𝘹𝘪𝘳𝘪𝘴 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴 𝘴𝘩𝘰𝘸𝘯 𝘢𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.

19/08/2026

Why Hexiris exists? During humanitarian mission work in underserved regions, Drs. Houfar Sekhavat and Nir Shoham-Hazon kept encountering the same problem: effective treatments existed - but access to them did not.

Hexiris was founded to close that gap, with technologies that are innovative, practical, scalable, and accessible across diverse healthcare settings.

Two practicing ophthalmologists. One mission: expanding access to interventional glaucoma care.

𝘈𝘭𝘭 𝘏𝘦𝘹𝘪𝘳𝘪𝘴 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴 𝘴𝘩𝘰𝘸𝘯 𝘢𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.

13/08/2026

In Canada, median wait times for ophthalmic surgery have grown, and fewer procedures meet the 16-week benchmark. Behind every statistic is a patient losing visual field while waiting.

Glaucoma doesn't wait. Treatment shouldn't either. That;s why, office-based interventional glaucoma moves procedures out of the OR intending to reduce wait times and freeing OR capacity for the cases that truly need it.

Source: Regional trends in ophthalmic surgical wait times in Ontario, Canada - Can J Ophthalmol, 2022

𝘈𝘭𝘭 𝘏𝘦𝘹𝘪𝘳𝘪𝘴 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴 𝘴𝘩𝘰𝘸𝘯 𝘢𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.

10/08/2026

OBi™ Gon single-vector, bidirectional excisional goniotomy is intended to improve conventional outflow to reduce intraocular pressure.

• 4 distinct depths of TM pe*******on, aligned with the anatomical stack
• Intuitive cutting tool for reproducible procedures
• Quick learning curve
• Established CPT Category 1 reimbursement pathway

𝘈𝘭𝘭 𝘏𝘦𝘹𝘪𝘳𝘪𝘴 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴 𝘴𝘩𝘰𝘸𝘯 𝘢𝘳𝘦 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦.

Address

5085 Avenue Principale Est

E1A9T8

Website

https://hexiris.ca/

Alerts

Be the first to know and let us send you an email when Hexiris Ophthalmics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Hexiris Ophthalmics:

Want your practice to be the top-listed Clinic?

Country:

City: